Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs Abstract #1497

Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.
Aim(s): Evaluate whether NETest predicts responses to somatostatin analogs (SSAs) in a prospective clinical trial.
Materials and methods: Test set: n=35 SSA-treated (RECIST-evaluated) to establish cut-offs to differentiate stable from progressive disease. Prospective trial set: n=28 SSA-treated Grade 1 (n=12)/Grade 2 (n=16) GEP-NETs. CgA (ELISA, normal <109ng/ml) and NETest (qRT-PCR with multianalyte algorithmic analyses: scale, 0–100%). Blood was evaluated monthly prior to SSA injection. CT/MRI were undertaken at entry and 6 monthly until progression (RECIST 1.0).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, CgA, PCR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1212 Circulating Gene Transcript Analysis of Pancreatic NETs
Introduction: PNETs are aggressive with poor survival. Therapeutic agents are available but efficacy determination is limited by imaging insensitivity and the lack of effective blood biomarkers.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: Daniele Alaimo
Authors: Kidd M, Modlin I, Drozdov I, Alaimo D, ...
Keywords: PNET, NETest, PCR
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...
#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#1190 Blood Gene Transcript Analysis Predicts 68Ga- SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status
Introduction: Limitations of biomarkers and imaging are a concern in the identification of NET status and therapy response.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Kidd M, Modlin I, Drozdov I, ...
#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)
Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Authors: Modlin I M, Kidd M, Drozdov I, Alaimo D, ...
Keywords: biomarker, CgA, NET, PCR